OFFICE OF THE SECRETARY OF STATE
TOBIAS READ
SECRETARY OF STATE

MICHAEL KAPLAN
DEPUTY SECRETARY OF STATE

ARCHIVES DIVISION
STEPHANIE CLARK
DIRECTOR

800 SUMMER STREET NE
SALEM, OR 97310
503-373-0701

TEMPORARY ADMINISTRATIVE ORDER

INCLUDING STATEMENT OF NEED & JUSTIFICATION

DMAP 45-2026

CHAPTER 410
OREGON HEALTH AUTHORITY
HEALTH SYSTEMS DIVISION: MEDICAL ASSISTANCE PROGRAMS

FILED: 10/23/2026 11:45 AM
ARCHIVES DIVISION SECRETARY OF STATE & LEGISLATIVE COUNSEL

FILING CAPTION: Adopt the new High-Cost Drug Carve-Out List effective November 1, 2026

EFFECTIVE DATE: 11/01/2026 THROUGH 04/29/2027

AGENCY APPROVED DATE: 10/21/2026

CONTACT:
Darren Coffman
503-979-8391
darren.d.coffman2@oha.oregon.gov
500 Summer Street NE
Salem, OR 97301

Filed By:
Darren Coffman
Rules Coordinator

NEED FOR THE RULE(S):

In September 2025, OHA leadership and the Governor's office agreed to implement a number of changes effective January 2026 that would reduce costs and administrative burden for coordinated care organizations (CCOs). Starting January 1, 2026, select high-cost drugs are carved out from CCO capitation. This is referred to as the High-Cost Drug Carve-Out (HCDCO). OHA reviews prior authorization (PA) requests for HCDCO products. Approved treatments will be covered by OHA directly on a fee-for-service (FFS) basis according to FFS reimbursement rules. CCOs are responsible for everything else, including care coordination, drug administration, inpatient stays, transportation, etc.

As of May 1, 2026 there are 54 drugs on the HCDCO List. They all have a high cost ($500k or more per member per year) and treat a rare condition that has few, if any, other treatment alternatives. This temporary rule change is needed to adopt the new version of the HCDCO List effective November 1, 2026, which adds five drugs (with the brand name in parentheses): garetosmab (Pasatru), pariglasgene brecaparvovec (Genglycos), rebisufligene etisparvovec (Fayuvi), zilganersen (Zanvastro), zilurgisertib (Atebrioz).

JUSTIFICATION OF TEMPORARY FILING:

(1) Describe the specific consequences that result from the failure to immediately adopt, amend or suspend the rule(s):
CCOs would be required to pay for the new drugs the temp rule would add to the 11/1/2026 HCDCO List. The cost of such new drugs are factored into the trend rate for the capitation payments made to CCOs, but this adjustment is spread over all CCOs and would not offset the drug costs experienced by the individual CCO(s) that might have a member in need of this very expensive therapy. By not updating the HCDCO List sooner, this could materially impact the finances of a CCO experiencing a request for these high-cost drugs.

If a newly approved FDA drugs clearly qualify for inclusion on the HCDCO List and is not added to the list as soon as practicable, there will be confusion for the providers and administrative burden for the CCOs and OHA if it is added to the HCDCO List at a later time.

(2) who would suffer these consequences:
CCOs, OHA and providers

(3) why or how failure to immediately take rulemaking action would cause these consequences:
Leaving the rule as currently written would keep the reference to the current 5/1/2026 HCDCO List. The drugs being added to the 11/1/26 list by the temporary rule recently received FDA approval and could be requested to treat members at any time. Because they are new therapies, there may be some pent-up demand for individuals who would benefit from these treatments. This would expose a CCO, and in particular smaller CCOs, to the possibility of having to pay millions of dollars for a member needing these therapies, without any direct corresponding amounts received through their capitation payments.

Not adding these drugs to the HCDCO List through a temporary rule as soon as possible after they come to market, and adding it through permanent rulemaking instead, would create confusion with providers. They initially would need to request prior authorization from the CCO to provide the therapy for the member, but would later need to make the request to OHA for other members requiring the therapy in the future

(4) how the temporary action will avoid or mitigate those consequences:
The temporary rule will incorporate the change reflected in the November 1, 2026 HCDCO List.

DOCUMENTS RELIED UPON, AND WHERE THEY ARE AVAILABLE:

The 11/1/26 “High-Cost Drug Carve-Out List” available at www.orpdl.org.

AMEND: 410-141-3855

RULE TITLE: Pharmaceutical Services

RULE SUMMARY: Incorporates, by reference, the new High-Cost Drug Carve-Out (HCDCO) List. Five new drugs are being added to the HCDCO List effective November 1, 2026.

RULE TEXT:
(1) Prescription drugs are a covered service for conditions that are described in the funded region of the Prioritized List of Health Services, as described in OAR 410-141-3820. CCOs shall pay for covered prescription drugs except:
(a) As otherwise provided, mental health drugs that are in Standard Therapeutic Class 7 (ataractics-tranquilizers) or Standard Therapeutic Class 11 (psychostimulants-antidepressants) (based on the National Drug Code (NDC) as submitted by the manufacturer to First Data Bank) and are dispensed through a licensed pharmacy;
(b) FDA-approved formulations of valproic acid and its derivatives, lamotrigine, and xanomeline/trospium and those drugs used to treat severe mental health conditions that the Authority specifically carved out from capitation according

to section (11) of this rule. This only includes those prescription drugs dispensed through a licensed pharmacy;
(c) Drugs covered under Medicare Part D when the member is fully dual eligible; and
(d) Prescriptions for Physician Assisted Suicide under the Oregon Death with Dignity Act, for which payment is governed by OAR 410-121-0150.
(e) Drugs appearing on the High-Cost Drug Carve-Out (HCDCO) List dated 11/1/2026, appearing at www.orpdl.org, and included here by reference. CCOs will be responsible for all other associated costs, including non-emergency medical transportation, care coordination, inpatient hospital services and other medically necessary expenses.
(A) The HCDCO List is limited to drugs determined by the Authority to present extreme financial uncertainty for CCOs. Drugs meeting the following general criteria will be considered by the Authority for inclusion on the HCDCO List:
(i) Have an estimated acquisition cost of $500,000 or more per member over a 12-month period;
(ii) Are indicated for very rare conditions; and
(iii) Have few alternatives, as determined by the Authority.
(B) To add a drug to or remove a drug from the HCDCO List, the CCO shall submit a request to the Authority containing all the following information:
(i) The drug name;
(ii) Whether the drug is recommended to be added to or removed from the HCDCO List;
(iii) The estimated per member acquisition cost of the drug for a 12-month period;
(iv) The FDA-approved indications for the drug;
(v) Any alternative treatments to the drug for these indications; and
(vi) Any additional considerations the Authority should give to adding or removing the drug, such as how the drug presents a financial risk to the CCO which is not adequately contemplated in current capitation rates.
(C) If the Authority approves a CCO request for a drug to be added to or removed from the HCDCO List, the Authority shall revise the HCDCO List and amend subsection (e) of this section (1) according to the rulemaking process described in ORS 183.333-183.335.
(i) For existing drugs whose carve out will have an impact on capitation rates as determined by OHA, the effective date of the change will be:
(I) The following January 1st, for requests submitted before April 1st; or
(II) One year from the following January 1st, for requests submitted on or after April 1st.
(ii) For new drugs or drugs whose carve out will not have an impact on capitation rates as determined by OHA, the effective date of the change will be:
(I) The following May 1st, for requests submitted before April 1st;
(II) The following August 1st, for requests submitted before July 1st;
(III) The following November 1st, for requests submitted before October 1st;
(IV) The following February 1st, for requests submitted before January 1st.
(D) The Authority may add a drug to or remove a drug from the HCDCO List at any time using the rulemaking process described in ORS 183.333-183.335.
(2) CCOs may use the statewide Practitioner-Managed Prescription Drug Plan under ORS 414.330 to 414.337.
(3) CCOs may use a preferred drug list if it allows access to other drug products not on the drug list through prior authorization.
(4) As specified in 45 CFR 156.122 and 42 CFR 438.10, CCOs shall publish up-to-date, accurate, and complete preferred drug lists, including any tiering structures, that have been adopted and any coverage criteria or other restrictions on the way certain drugs may be obtained. CCOs shall ensure that:
(a) The preferred drug list is easily accessible to members and potential members, state and federal government, and the public;
(b) The preferred drug list is accessible on the CCO's public website in a machine-readable format through a clearly identifiable web link or tab without requiring a member to access account or policy number;
(c) Be made available in paper form if requested by a member; and

(d) If a CCO has more than one plan, members may be easily able to discern which preferred drug list applies to which plan.
(5) The preferred drug list shall:
(a) Include Federal Drug Administration (FDA) approved drug products for each therapeutic class sufficient to ensure the availability of covered drugs with minimal prior approval intervention by the provider of pharmaceutical services;
(b) Include at least one item in each therapeutic class of over-the-counter medications; and
(c) Be revised periodically to assure compliance with this requirement.
(6) CCOs shall cover at least one form of contraception within each of the 18 methods identified by the FDA. As set forth in OAR 410-141-3515, the member may refer themselves directly to family planning services without getting a referral from a PCP or other participating providers.
(7) Prior Authorization for prescription drug requests shall be addressed by the CCOs as described in OAR 410-141-3835.
(8) CCOs shall authorize the provision of a drug requested by the Primary Care Provider or referring provider if the prescriber certifies medical necessity for the drug such as:
(a) The equivalent of the drug listed has been ineffective in treatment; or
(b) The drug listed causes or is reasonably expected to cause adverse or harmful reactions to the member.
(9) CCOs must not authorize payment for any Drug Efficacy Study Implementation (DESI) Less Than Effective (LTE) drugs that have reached the FDA Notice of Opportunity for Hearing (NOOH) stage, as specified in OAR 410-121-0420 (DESI)(LTE) Drug List. DESI LTE drugs are identified by the Covered Outpatient Drug (COD) Status equal to 05 or 06 in the federal "Drug Products in the Medicaid Drug Rebate Program" list available at: https://data.medicaid.gov/
(10) The Authority shall pay for a drug that is not included in the global budget pursuant to the Pharmaceutical Services program rules (chapter 410, division 121), unless otherwise provided in this rule. A CCO must not reimburse providers for drugs carved-out in section (1) of this rule.
(11) Making changes to the carve-out list of mental health drugs in subsection (1)(b) of this rule:
(a) Adding mental health drugs to the carve-out list.
(A) A CCO may seek to add drugs by submitting a request to the Authority. The request must contain all the following information:
(i) The drug name;
(ii) The FDA-approved indications that identify the drug may be used to treat a severe mental health condition, along with any other FDA-approved indications; and
(iii) The reason the Authority should consider this drug for carve out.
(B) If the Authority approves a CCO request for a drug not to be paid within the global budget, the Authority shall:
(i) Amend subsection (1)(b) of this rule according to the process described in ORS 183.335(5) within sixty (60) days of the request to exclude the drug from the global budget if the Authority determines that the drug has an approved FDA indication for the treatment of a severe mental health condition such as major depressive, bi-polar, or schizophrenic disorders;
(ii) Within 180 days of amending subsection (1)(b) of this rule as described in subsection (i), adopt this same amendment to subsection (1)(b) using the permanent rulemaking process described in ORS 183.335(1)-(4).
(C) The Authority may add drugs at any time using the rulemaking process described in ORS 183.333-183.335.
(b) Removing mental health drugs from the carve-out list.
(A) A CCO may seek to remove drugs by submitting a request to the Authority no later than March 1 of any contract year. The request must contain all the following information:
(i) The drug name;
(ii) The FDA approved indications for the drug; and
(iii) The reason the Authority should consider removing this drug from the list of carved out drugs.
(B) If the Authority approves a CCO request for a carved-out drug to be paid within the global budget, the Authority shall include the drug in the global budget for the following January contract cycle.

(C) The Authority may remove drugs in conjunction with a January contract cycle using the rulemaking process described in ORS 183.333-183.335.
(12) CCOs shall submit quarterly encounter data within 45 days after the end of the quarter pursuant to 42 CFR 438.3.
(13) CCOs are encouraged to provide payment only for outpatient and physician-administered drugs produced by manufacturers that have valid rebate agreements in place with the CMS as part of the Medicaid Drug Rebate Program. CCOs may continue to have some flexibility in maintaining preferred drug lists regardless of whether the manufacturers of those drugs participate in the Medicaid Drug Rebate Program.
(14) CCOs shall utilize a Pharmacy and Therapeutics (P&T) committee and a Drug Use Review (DUR) program. The committees may work in tandem or independent of the other, if all committee requirements for both committee types are met:
(a) A P&T committee must maintain written documentation of the rationale for all decisions regarding the drug list development and revisions. The committee shall follow the membership and meeting standards specified in 45 CFR § 156.122(3)(i) and (ii). Meetings shall be held at least quarterly;
(b) CCOs shall provide a detailed description of its P&T committee including its DUR functions on an annual basis. The report shall be in the form and manner required by the OHP. The data requested by the Authority shall be calculated to meet federal reporting obligations;
(c) The committee in its DUR capacity shall assure prescriptions are appropriate, medically appropriate, and not likely to result in adverse medical results. The committee must be designed to educate prescribers and pharmacists to identify and reduce the frequency of patterns of fraud, abuse, gross overuse, or inappropriate or medically unnecessary care. The committee shall include prospective DUR, retrospective DUR, and educational programs as each is defined and described by 42 CFR 456, subpart K and Section 1902(oo) of the Social Security Act [42 U.S.C. 1396a(oo)].
(15) As required by ORS 414.328, CCOs shall implement a synchronization policy for the dispensing of prescription drugs to members of the CCO. A “synchronization policy” means a procedure for aligning the refill dates of a patient’s prescription drugs so that drugs that are refilled at the same frequency may be refilled concurrently.
(16) Enrolled providers are required to check the Prescription Drug Monitoring Program (PDMP) as defined in ORS 431A.655 before prescribing a schedule II controlled substance pursuant to 42 U.S.C 1396w-3a:
(a) Providers shall maintain documentation of the prescription drug history of the individual being treated; and
(b) In the case that an enrolled provider is not able to conduct the PDMP check, the providers shall maintain documentation of efforts, including reasons why the provider was unable to conduct the check;
(c) The PDMP check does not apply to clients in exempt populations:
(A) Individuals receiving hospice care;
(B) Individuals receiving palliative care;
(C) Individuals receiving cancer treatment;
(D) Individuals with sickle cell disease;
(E) Residents of long-term care facilities described in 42 U.S.C. 1396d, or of another facility for which frequently abused drugs are dispensed for residents through a contract with a single pharmacy in accordance with 42 U.S.C. 1396w–3a(h)(2)(B); and
(F) Individuals admitted to an inpatient hospital facility. This exemption shall only apply to schedule II controlled substances provided or administered to the individual admitted to the inpatient hospital facility.
(d) PDMP requirements are in accordance with OAR 333-023-0800 to 333-023-0830.

STATUTORY/OTHER AUTHORITY: ORS 413.042, 414.572, 414.591, 414.605

STATUTES/OTHER IMPLEMENTED: ORS 414.570–414.686